相关临床试验
349
99 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1992
进行中（未招募）
92
26.4%
已完成
154
44.1%
尚未招募
7
2.0%
招募中
30
8.6%
暂停
3
0.9%
终止
14
4.0%
Unknown
43
12.3%
撤回
6
1.7%
暂无批准数据
- Severe pneumonia comprises three distinct biological subtypes, or "pneumotypes," that are indistinguishable by standard clinical presentation but strongly linked to patient recovery trajectories. - The most common subtype (49% of cases) features immune suppression and lung lining damage with minimal inflammation, potentially explaining why anti-inflammatory therapies fail or harm some patients. - A balanced immune response subtype (23% of cases) was associated with the fastest recovery and shortest ventilator time, despite initially comparable illness severity. - The most dangerous subtype showed persistent severe inflammation with immature immune cells, and these patients may benefit most from targeted anti-inflammatory therapies.
- Researchers at the Wellcome Sanger Institute combined whole-genome sequencing with decades of clinical data to trace how myeloproliferative neoplasms (MPNs) evolve over time. - Patients with stable disease showed genetically "steady" blood cell populations, while those who progressed acquired new DNA mutations detectable years before clinical deterioration. - Some patients lacking JAK2, CALR, or MPL mutations showed genomic patterns consistent with normal aging rather than cancer, challenging current diagnostic assumptions. - A separate Danish population study found that the JAK2V617F mutation does not always lead to cancer, with only 37 of 67 mutation carriers developing MPN over a 10-year period.
- Scientists at the Wellcome Sanger Institute created IBDverse, the largest single-cell dataset from gut tissue and blood, analyzing gene expression in roughly 2.2 million individual cells from over 400 individuals. - The study identified likely effector genes at more than half of known IBD genetic risk regions, revealing that many genetic effects appear only in specific cell types like dendritic cells and epithelial cells. - Findings suggest IBD arises from a combination of immune system dysregulation through reduced Notch signaling and failure of the gut lining to repair itself via disrupted Wnt-regulated genes. - The single-cell genetic mapping framework demonstrated broader applications, including explaining metformin's gastrointestinal side effects and potential use in asthma, psoriasis, and endometriosis.
- Cyclana Bio received Health Research Authority approval for its 500-patient PEMP observational study investigating endometriosis mechanisms affecting 1 in 10 women. - The company will use human tissue and menstrual fluid samples to build 3D disease models and identify novel druggable targets for therapeutic development. - The study aims to determine whether endometriosis requires a single treatment approach or personalized medicine based on tissue-level dynamics and extracellular matrix involvement. - First patients have been recruited at Peterborough City Hospital and the Rosie Hospital Cambridge, with the study funded by Cyclana Bio's £5M pre-seed round.
- The PIONEER trial demonstrates that adding low-dose megestrol acetate to standard anti-estrogen therapy significantly reduces tumor growth rates in ER-positive breast cancer patients within two weeks of treatment. - Both 40mg and 160mg daily doses of megestrol acetate showed comparable anti-cancer effects when combined with letrozole, suggesting the lower dose provides therapeutic benefit with fewer side effects. - The synthetic progesterone mimic addresses a dual clinical need by simultaneously slowing tumor progression and managing troublesome hot flushes that often lead patients to discontinue anti-estrogen therapy. - Laboratory studies revealed that progesterone indirectly blocks estrogen receptors and stops ER-positive cancer cells from dividing, providing mechanistic support for the clinical findings.
- The National Institute for Health and Care Research is piloting a 'Just in Time' scheme that could reduce clinical trial setup time from months to days, potentially improving patient access to trials closer to home. - The initiative is being tested in the PemOla trial, which explores combination immunotherapy using pembrolizumab and olaparib for pancreatic cancers with high genetic mutation burden. - Pancreatic cancer remains one of the most challenging cancers to treat, with only 5% of patients surviving more than 10 years and limited progress in outcomes over the past 50 years. - The scheme enables hospitals to join trials when eligible patients are identified, potentially accelerating recruitment and speeding development of precision medicines for rare patient groups.
- A new "pill-on-a-string" capsule sponge test successfully identified 54% of Barrett's esophagus patients as low-risk, potentially eliminating the need for invasive endoscopy surveillance in these cases. - The study of 910 patients across 13 U.K. hospitals found only 0.4% of low-risk patients had high-risk cellular changes on follow-up endoscopy, with no cancers detected in this group. - The capsule test offers significant advantages over traditional endoscopy, requiring no sedation, allowing immediate return to work, and being administered quickly by nurses with minimal training. - Researchers plan to enhance the technology with improved laboratory analysis and artificial intelligence to further optimize Barrett's esophagus risk stratification.
- Mary Catchpole, 19, becomes the first European patient to receive leniolisib (Joenja), a newly approved targeted treatment for activated PI3-kinase delta syndrome (APDS), a rare inherited immune disorder. - The drug works by inhibiting an overactive enzyme that disrupts immune function, offering a potential cure for patients who previously faced lifelong infections and invasive treatments. - APDS was discovered by Cambridge researchers in 2013 with help from Catchpole's family, who lost four members to the condition before this breakthrough treatment became available. - The NHS approved leniolisib at a list price of £352,000 per year with a confidential discount, potentially benefiting up to 50 patients over age 12 in England.
- The NHS will be the first health system in Europe to trial histotripsy, a non-invasive ultrasound technology that destroys liver tumors using sound waves to create "bubble clouds" that pulverize cancer cells. - The treatment takes just 30 minutes with limited pain and quick recovery, offering an alternative to surgery for patients with primary and secondary liver cancers at Addenbrooke's Hospital in Cambridge. - Clinical trial data shows 73.3% one-year survival rates for primary liver cancer patients and 48.6% for secondary tumors, with over 1,500 patients worldwide already treated using this FDA-approved technology. - Health Secretary Wes Streeting fast-tracked approval through the new Innovative Devices Access Pathway, potentially expanding treatment to pancreatic and kidney cancers in the future.
- A groundbreaking clinical trial led by Addenbrooke's Hospital demonstrates 100% three-year survival rate for patients with BRCA-mutated breast cancer when treated with olaparib plus chemotherapy before surgery. - The innovative "Partner" trial revealed that administering olaparib 48 hours after chemotherapy creates a therapeutic window that maximizes treatment efficacy while allowing bone marrow recovery. - This treatment approach could potentially transform care for approximately 1,200 UK patients annually with inherited BRCA mutations and may extend to other BRCA-related cancers including ovarian, prostate, and pancreatic.
